Rationale and Design of the REPEAT Trial: A Multicenter Randomized Trial Comparing Redo Surgical Aortic Valve Replacement to Valve‐in‐Valve Transcatheter Aortic Valve Replacement
Journal of the American Heart Association · 20.05.2025 · 14 (10)
DOI: 10.1161/jaha.125.040954 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.05.2025. Verfasst von Matthias Raschpichler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery Heart Center Leipzig at Leipzig University Leipzig Germany. Hauptthemen laut MEDLINE: Aortic Valve, Aortic Valve Stenosis, Bioprosthesis, Heart Valve Prosthesis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background Redo surgical aortic valve replacement (rSAVR) has for long been the therapeutic reference standard for degenerated surgical aortic bioprostheses. Valve‐in‐valve transcatheter aortic valve replacement (ViV‐TAVR) has emerged as an alternative for patients at high surgical risk due to its lower invasiveness. The long‐term clinical efficacy of ViV‐TAVR in patients at low to intermediate surgical risk remains unknown. Methods and Results To compare clinical outcomes of redo surgical aortic valve replacement versus ViV‐TAVR in low‐ to intermediate‐risk patients with degenerated surgical aortic bioprostheses. REPEAT (Repeat Intervention for Deteriorated Surgical Bioprosthetic Aortic Valves) is an investigator‐initiated, international, multicenter, randomized, parallel, open‐label trial. A total of 890 patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac Surgery Heart Center Leipzig at Leipzig University Leipzig Germany.
- Department of Rhythmology University Hospital Schleswig-Holstein, Campus Lübeck Lübeck Germany.
- Department of Cardiology University Heart & Vascular Center Hamburg Hamburg Germany.
- Department of Population Health Science and Policy Icahn School of Medicine at Mount Sinai New York NY USA.
- Department of Computational Biomedicine Cedars-Sinai Medical Center Los Angeles CA USA.
- Smidt Heart Institute, Department of Interventional Cardiology, Cedars-Sinai Medical Center Los Angeles CA USA.
ORCID-Profile: Matthias Raschpichler, Stefan Blankenberg, Marcio A Diniz, Emilia Bagiella, Vinicius F Calsavara, Aakriti Gupta, Niklas Schofer, Tsuyoshi Kaneko, Mohamed Abdel-Wahab, Holger Thiele, Michael A Borger
Zitieren
APA
Raschpichler, M., de Waha, S., Blankenberg, S., Diniz, M. A., Bagiella, E., Gelijns, A. C., Calsavara, V. F., Gupta, A., Schofer, N., Kaneko, T., Abdel-Wahab, M., Thiele, H., Makkar, R., & Borger, M. A. (2025). Rationale and Design of the REPEAT Trial: A Multicenter Randomized Trial Comparing Redo Surgical Aortic Valve Replacement to Valve‐in‐Valve Transcatheter Aortic Valve Replacement. Journal of the American Heart Association, 14(10). https://doi.org/10.1161/jaha.125.040954
Vancouver
Raschpichler M, de Waha S, Blankenberg S, Diniz MA, Bagiella E, Gelijns AC, et al. Rationale and Design of the REPEAT Trial: A Multicenter Randomized Trial Comparing Redo Surgical Aortic Valve Replacement to Valve‐in‐Valve Transcatheter Aortic Valve Replacement. Journal of the American Heart Association. 2025;14(10). doi:10.1161/jaha.125.040954
BibTeX
@article{Raschpichler2025,
author = {Raschpichler, Matthias and de Waha, Suzanne and Blankenberg, Stefan and Diniz, Marcio A and Bagiella, Emilia and Gelijns, Annetine C and Calsavara, Vinicius F and Gupta, Aakriti and Schofer, Niklas and Kaneko, Tsuyoshi and Abdel-Wahab, Mohamed and Thiele, Holger and Makkar, Raj and Borger, Michael A},
title = {Rationale and Design of the REPEAT Trial: A Multicenter Randomized Trial Comparing Redo Surgical Aortic Valve Replacement to Valve‐in‐Valve Transcatheter Aortic Valve Replacement},
journal = {Journal of the American Heart Association},
year = {2025},
volume = {14},
number = {10},
doi = {10.1161/jaha.125.040954}
}
EUVIMED